Changes in Beneficial Ownership · 4
Kamada Ltd.
KMDANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-27
- Issuer
- KAMADA LTD
- Issuer CIK
- 0001567529
- Trading symbol
- KMDA
Reporting owner 1
- Name
- Goldwasser Karnit
- Reporting owner CIK
- 0002071721
- Relationship
- Director
- Address
- 2 HOLTZMAN ST., REHOVOT, ISRAEL, L3
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | 7.41[F1][F4] | 2026-08-27 | A · Form 4 | 26,500 | A | 0.00 | [F2] | [F2] | Ordinary Shares | 26,500 | 26,500 | I | Held by trustee[F3] |
| Employee Stock Option (right to buy) | 5.99[F1][F5] | 2026-08-27 | A · Form 4 | 30,000 | A | 0.00 | [F2] | [F2] | Ordinary Shares | 30,000 | 30,000 | I | Held by trustee[F3] |
| Employee Stock Option (right to buy) | 7.38[F1][F6] | 2026-08-27 | A · Form 4 | 30,000 | A | 0.00 | [F2] | [F2] | Ordinary Shares | 30,000 | 30,000 | I | Held by trustee[F3] |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- I
- Indirect
Footnotes
- F1
- The exercise prices of all options reported in this Form 4 are denominated in New Israeli Shekels (NIS). For presentation purposes, all exercise prices presented in this Form 4, including those referenced in the footnotes, are presented in U.S. dollars (USD) based on the NIS/USD exchange rate published by the Bank of Israel as of September 22, 2026.↩ 1↩ 2↩ 3
- F2
- The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6
- F4
- This option was previously reported as covering 26,500 ordinary shares at an exercise price of $7.58. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.↩ 1
- F5
- This option was previously reported as covering 30,000 ordinary shares at an exercise price of $6.15. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.↩ 1
- F6
- This option was previously reported as covering 30,000 ordinary shares at an exercise price of $7.55. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.↩ 1
Signature 1
- Signed
- /s/ Karnit Goldwasser
- Date
- 2026-09-24
Company context
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business